Displaying 1081 - 1100 of 1505
Announced Action for January 27, 2006
Preserving Competition, FTC Requires Divestitures Before Allowing Tevas $7.4 Billion Acquisition of IVAX
Commission Finds That North Texas Specialty Physicians Illegally Fixed Prices
In re Tamoxifen Citrate Antitrust Litigation
Announced Action for November 18, 2005
FTC Sues to Stop Anticompetitive Agreement in U.S. Drug Industry
Administrative Law Judge Orders Evanston Northwestern Healthcare Corporation to Sell Highland Park Hospital
FTC Accepts Settlement to Remedy DaVita's Acquisition of Rival Outpatient Dialysis Clinic Provider Gambro
Health Care: An Interview with Commissioner Thomas B. Leary
Partners Health Network, Inc., In the Matter of
Novartis AG, In the Matter of (Eon Labs, Inc)
To resolve competitive concerns for three generic pharmaceuticals that arose from Novartis AG’s acquisition of Eon Labs, Inc., Novartis agreed to divest all the assets necessary to manufacture and market generic desipramine hydrochloride tablets, orphenadrine citrate extended release (ER) tablets, and rifampin oral capsules in the United States to Amide within 10 days of Novartis’s acquisition of Eon. Further, Novartis, through its Sandoz generic pharmaceuticals division, will supply Amide with orphenadrine citrate ER and desipramide hydrochloride tablets until Amide obtains FDA approval to manufacture the products itself, and will assist Amide in obtaining all necessary FDA approvals.
Announced Action for September 20, 2005
White Sands Health Care System, L.L.C.; et al., In the Matter of
FTC Issues Report on PBM Ownership of Mail-Order Pharmacies
Announced Action for August 19, 2005
South Carolina Physician-hospital Organization Agrees To Settle Physician Price-fixing Charges
Protecting Competition, the Federal Trade Commission Approves Novartis AGs Acquisition of Eon Labs
Announced Action for July 5, 2005
Displaying 1081 - 1100 of 1505